医药生物行业炎症性肠病:市场空间大 研发路径愈发清晰 中国创新药公司有望深度参与

天风证券
Jan 09

IBD 的患者人群庞大,且存在未满足的治疗需求,2024 年药物销售规模约240 亿美金炎症性肠病(IBD,含溃疡性结肠炎UC/克罗恩病CD)对生活质量影响显著。全球层面近30 年患者规模快速扩张,1990-2017 年全球IBD 患者数由约370万增至超过680 万,增幅约85%。中国处在新病例增长阶段,患者增长更快:2021 年中国IBD 患者新增病例约2.49 万;发病率1990-2019 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10